Clinical Trial Record

Return to Clinical Trials

Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer


1995-09


N/A


2007-06


48

Study Overview

Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy combined with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of brachytherapy followed by external-beam radiation therapy plus chemotherapy in treating patients who have pancreatic cancer that cannot be removed surgically.

OBJECTIVES: * Determine the response/remission rate, survival, and degree of local control from interstitial colloidal phosphorus P32 followed by external beam radiotherapy and chemotherapy in patients with unresectable pancreatic cancer. OUTLINE: Patients are stratified according to prior therapy (yes vs no). Patients receive dexamethasone intratumorally, then macroaggregated albumin and interstitial phosphorus P32 intratumorally. Most patients receive a second course of this brachytherapy. Patients then proceed to chemoradiotherapy beginning 7-14 days after brachytherapy. Radiotherapy is administered 5 days a week for 6.4 weeks. Fluorouracil IV is administered every other day for 4 doses during weeks 1 and 2. Patients are followed monthly for 1 year then every 3 months thereafter. PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.

  • Pancreatic Cancer
  • DRUG: dexamethasone
  • DRUG: fluorouracil
  • RADIATION: brachytherapy
  • RADIATION: phosphorus P32
  • RADIATION: radiation therapy
  • CMM-95079
  • CDR0000064415 (REGISTRY Identifier) (REGISTRY: PDQ (Physician Data Query))
  • CH/UMC-95079
  • NCI-V95-0760

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

1999-11-01  

N/A  

2013-07-17  

2003-01-26  

N/A  

2013-07-18  

2003-01-27  

N/A  

2007-06  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
Primary Outcome MeasuresMeasure DescriptionTime Frame
Response rate
Duration of remission
Survival
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Patterns of failure

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    DISEASE CHARACTERISTICS:

  • Histologically proven unresectable adenocarcinoma of the pancreas limited to the head, body, or tail of the pancreas


  • Diameter no greater than 5 cm
  • Volume no greater than 66 mL
  • No ascites (with or without tumor cells)
  • No endoscopically proven tumor penetration of duodenum or stomach

  • PATIENT CHARACTERISTICS:
    Age:

  • 18 and over

  • Performance status:

  • Karnofsky 70-100%

  • Hematopoietic:

  • WBC at least 3,000/mm3
  • Platelet count at least 100,000/mm3
  • Hemoglobin at least 9 g/dL (transfusion allowed)

  • Hepatic:

  • No hepatic disease
  • At least 50% uptake of technetium-sulfur colloid in normal liver if cirrhosis suspected
  • No vascular occlusion of portal system

  • Renal:

  • Creatinine no greater than 1.5 mg/dL
  • BUN no greater than 25 mg/dL

  • Other:

  • No Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
  • Not pregnant

  • PRIOR CONCURRENT THERAPY:
    Biologic therapy:

  • Not specified

  • Chemotherapy:

  • If prior chemotherapy, test dose of colloidal phosphorous P32 administered prior to attempted treatment

  • Endocrine therapy:

  • Not specified

  • Radiotherapy:

  • No prior radiotherapy to pancreas, liver, or upper gastrointestinal tract

  • Surgery:

  • No complete surgical resection
  • No splenectomy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • STUDY_CHAIR: Stanley E. Order, MD, ScD, FACR, Center for Molecular Medicine

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available